Founding Partner
Most life sciences patent applications that run into trouble at the USPTO do not fail because the science is weak. They fail because of avoidable mistakes in the specification, the claims, or the prosecution process itself. This post covers the pitfalls that show up most often and what to do about them.
Every life sciences company that has been through USPTO prosecution has a story about something that went wrong. A claim that was narrowed more than it needed to be. An application that was abandoned over a missed deadline. A specification that could not support the scope of the claims.
These are not rare edge cases. They are the pitfalls that Gearhart Law sees in application after application, and they are almost always preventable.
Pitfall 1: A Specification That Cannot Support the Claims
The specification is the written description of your invention. It has to do two things: show that you actually had the invention when you filed, and teach someone skilled in the field how to make and use it. In life sciences, where claims often cover broad classes of compounds or methods, a specification that falls short on either count creates problems that are very hard to fix after filing.
Too Few Working Examples
A specification that describes a broad genus of compounds but only provides experimental data for one or two species is vulnerable to both written description and enablement rejections. The examiner will argue that you have not shown the invention works across the full scope of what you are claiming.
The fix is to include as many working examples as the science allows at the time of filing. If you are still early in the research, a provisional application can lock in your priority date while you build out the data package for the formal filing.
Insufficient Disclosure of the Best Mode
Under 35 U.S.C. § 112(a), you are required to disclose the best mode of practicing your invention that you know of at the time of filing. In life sciences, this often means disclosing the specific formulation, dosing regimen, or synthetic route that your team has found to work best.
Holding back the best mode to protect trade secrets while claiming broad patent protection is a violation of this requirement and a basis for challenging a patent.
Vague or Functional Descriptions Without Structural Support
Describing your invention purely in terms of what it does, without structural definition, gives examiners grounds to challenge both written description and enablement.
A compound defined only by its ability to inhibit a specific enzyme covers every compound that achieves that result, including ones you have never made or tested. The specification needs to provide enough structural information to show you had what you are claiming.
Pitfall 2: Claims That Are Either Too Broad or Too Narrow
Claim drafting in life sciences is a balancing act. Claims that are too broad will face rejections. Claims that are too narrow give competitors room to design around your patent. Both outcomes undermine the value of the application.
Claiming the Result Instead of the Method
A claim that covers any compound or method that achieves a particular result, without specifying how, is a functional claim at its broadest. These claims attract scrutiny. If the specification does not demonstrate how to achieve the result across the full scope of the claim, the examiner will issue an enablement rejection.
The stronger approach is to claim the specific structural features or process steps that produce the result, with functional language as a supplement rather than the sole basis for the claim.
Genus Claims Without Adequate Species Support
A genus claim covers a broad class of compounds or methods. It is the most valuable type of claim in pharmaceutical and biotech patenting because it blocks competitors from working within the entire class. But a genus claim not supported by enough species examples in the specification will face a written description rejection.
The key question is whether the specification demonstrates possession of the genus as a whole, or just a few isolated members of it. The more diverse and representative the examples, the stronger your genus claim.
Missing Dependent Claims
Dependent claims narrow an independent claim by adding additional limitations. They serve as fallback positions if the independent claim is rejected or later challenged. Life sciences applications that rely on a single broad independent claim with no dependent claims are leaving themselves exposed. If the independent claim falls, there is nothing left to argue.
A well-structured claim set includes independent claims at different levels of breadth, with dependent claims that add specificity at each level.
The patent attorneys at Gearhart Law can review your specification and claims before you submit. Reach out for a free half-hour consultation.
Pitfall 3: Prosecution Process Mistakes That Cost You the Application
Some of the most damaging pitfalls in life sciences patent prosecution have nothing to do with the science. They are procedural mistakes that can abandon a valid application or limit your rights in ways that are difficult or impossible to undo.
Missing Response Deadlines
When the USPTO issues an Office Action, you have a set period to respond, typically three months without extension fees, and up to six months with fees. Missing the deadline without requesting an extension results in the application being abandoned.
Reviving an abandoned application is possible but expensive and not always successful. Every Office Action response deadline should be calendared the day the action arrives, with reminders set well in advance.
Making Unnecessary Claim Amendments
Every amendment you make to your claims during prosecution becomes part of the prosecution history. That history can be used against you in litigation to narrow the scope of your patent through a doctrine called prosecution history estoppel. Amending claims unnecessarily, or more broadly than the rejection requires, can give up rights you did not need to surrender.
The principle is to amend only what is necessary to overcome the rejection and to make clear in the response why the amendment is being made and what scope is being preserved.
Failing to Disclose Known Prior Art
Every person involved in the prosecution of a U.S. patent application has a duty of candor to the USPTO. This includes disclosing prior art that is material to patentability that you are aware of.
Failing to disclose known prior art can result in a finding of inequitable conduct, which can render the entire patent unenforceable. The duty applies throughout the prosecution and is not limited to what you include in the initial application.
Not Filing a Continuation Before the Parent Issues
Once a patent issues, the window to file certain types of continuation applications closes. Life sciences companies that do not have a continuation strategy in place before their patent issues may miss the opportunity to pursue broader claims and claim-specific embodiments developed after the original filing, or adapt their coverage to respond to competitor activity. A continuation filing decision should be part of every pre-issuance review.
Pitfall 4: Poor Coordination Between U.S. and International Prosecution
Life sciences companies almost always need patent protection in multiple markets. Managing U.S. and international prosecution in isolation creates pitfalls that can undermine your global portfolio.
Filing PCT Without a U.S. Strategy in Place
A Patent Cooperation Treaty (PCT) application preserves your right to seek protection in over 150 countries through a single international filing. But a PCT application that is not coordinated with your U.S. prosecution strategy can create problems.
Amendments made during the international phase can affect the scope of claims available in the U.S. national phase. Decisions about which claims to pursue internationally should be made with U.S. prosecution in mind from the start.
Inconsistent Claim Scope Across Jurisdictions
The claims granted in the U.S. and in other countries for the same invention often end up looking different because each patent office applies its own standards. This becomes a problem when the differences create gaps in coverage that competitors can exploit.
Coordinating claim strategy across jurisdictions, with a single attorney or team overseeing the global portfolio, reduces the risk of inconsistency.
Avoid the Pitfalls Before They Cost You
Most life sciences patent prosecution problems are preventable. A specification with strong working examples. Claims that are broad enough to matter and narrow enough to survive. A prosecution process that stays on schedule, discloses what it should, and plans for a continuation strategy before the parent issues.
Gearhart Law works with life sciences companies throughout New Jersey and beyond to prepare and prosecute pharmaceutical, biotechnology, and medical device patents that hold up.
Richard Gearhart and our team bring both the scientific training and the legal depth this work requires. Leave your details, and we will be in touch, or call 908.273.0700 for a free half-hour consultation.
Frequently Asked Questions With Life Sciences Patent Applications at the USPTO
1. What are the most common reasons life sciences patent applications get rejected?
The most common rejections are written description rejections, enablement rejections, and Section 101 subject matter eligibility rejections. Written description and enablement rejections usually happen when the claims are broader than what the specification actually demonstrates. Section 101 rejections arise when the examiner believes the claims are directed to a natural phenomenon or abstract idea rather than a specific technical application. The patent prosecution team at Gearhart Law handles all three types regularly.
2. What is the duty of candor, and what happens if you violate it?
The duty of candor requires everyone involved in a U.S. patent application to disclose prior art and other information that is material to patentability. Violating this duty by withholding known prior art can result in a finding of inequitable conduct, which makes the patent unenforceable even if it was validly granted. It is a serious risk that applies throughout the life of the application, not just at filing.
3. How many working examples do I need in my specification?
There is no fixed number required by the USPTO. What matters is whether the examples are diverse and representative enough to support the full scope of your claims. A specification claiming a broad genus of compounds that only includes one or two working examples for a narrow subset is vulnerable to written description and enablement rejections. If you are filing early in your research, a provisional application can lock in your priority date while you build out the data package.
4. What is prosecution history estoppel?
Prosecution history estoppel prevents a patent owner from claiming in litigation that their patent covers something they gave up during prosecution. If you amend a claim to overcome a rejection, you may not be able to argue later that the original broader scope still applies. This is why every amendment made during prosecution should be as narrow as necessary and clearly explained in the written response.
5. What happens if I miss an Office Action deadline?
Missing an Office Action response deadline without requesting an extension results in the application going abandoned. You may be able to revive it, but revival requires showing the delay was unintentional, paying fees, and responding to the outstanding Office Action. It is not guaranteed, and it adds cost and delay. Every Office Action deadline should be tracked carefully from the day the action arrives.
6. Should I file a continuation before my patent issues?
Yes, if there are claims you want to pursue that were not allowed in the parent application, or if you want to adapt your coverage as competitors enter the market. The window to file a continuation closes when the parent patent issues. A pre-issuance review of your pending application should be a standard part of your patent prosecution process. Talk to a patent attorney before the patent issues.
7. How does PCT filing affect my U.S. patent prosecution?
A PCT application preserves your right to seek protection in over 150 countries through a single filing. Amendments made during the international phase can affect what claims are available in the U.S. national phase. U.S. prosecution strategy should be considered before and during the international phase, not after you enter the U.S. national phase and find that prior amendments have narrowed your options.
8. How do I know if my life sciences patent application is ready to file?
Your application is ready to file when the specification includes enough working examples to support the full scope of your claims, the claims are drafted at the right level of breadth, you have disclosed all known prior art, and your filing timing aligns with your development and disclosure schedule. A legal patentability opinion and a specification review by an experienced life sciences patent attorney before filing can catch problems that are much more expensive to fix after an Office Action arrives.